The American Journal of Medicine
Volume 121, Issue 5 , Pages 426-432, May 2008

Is Serum Cystatin-C a Reliable Marker for Metabolic Syndrome?

  • Aude Servais, MD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France
    • Corresponding Author InformationRequests for reprints should be addressed to Aude Servais, MD, Service de Néphrologie, Hôpital Necker, 149 rue de Sèvres, Paris 75015, France.
  • ,
  • Philippe Giral, MD, PhD

      Affiliations

    • Cardiovascular Prevention Center, Pitié Salpêtrière Hospital, Paris, France
  • ,
  • Maguy Bernard, MD, PhD

      Affiliations

    • Department of Biochemistry, Pitié Salpêtrière Hospital, Paris, France.
  • ,
  • Eric Bruckert, MD, PhD

      Affiliations

    • Cardiovascular Prevention Center, Pitié Salpêtrière Hospital, Paris, France
  • ,
  • Gilbert Deray, MD, PhD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France
  • ,
  • Corinne Isnard Bagnis, MD, PhD

      Affiliations

    • Department of Nephrology, Pitié Salpêtrière Hospital, Paris, France

Abstract 

Purpose

Chronic kidney disease and metabolic syndrome are recognized as major cardiovascular risk factors. It has been shown that cystatin C has a stronger association with mortality risk than creatinine-based estimations of glomerular filtration rate. We measured cystatin values in dyslipidemic patients and looked for correlations between renal function, cystatin, and metabolic syndrome.

Methods

There were 925 dyslipidemic patients prospectively included in this cross-sectional study and evaluated over 10 months. Each visit included clinical and biological assessment.

Results

Most patients exhibited cardiovascular risk factors other than dyslipidemia: hypertension in 34%, diabetes in 11%, and smoking in 18%. Mean triglycerides were 149±136 mg/dL, mean high-density lipoprotein cholesterol 54±14 mg/dL, and low-density lipoprotein 167±48 mg/dL. Metabolic syndrome was present in 238 (26%) patients. Plasma creatinine did not differ between control group and metabolic syndrome patients (80±26 vs 82±20 μmol/L, respectively, P=.2), but creatinine clearance evaluated by abbreviated Modification of Diet in Renal Disease Study formula was lower in the metabolic syndrome group than in the non-metabolic-syndrome group (83.3±18.8 mL/min/1.73m2 vs 86.8±16.9 mL/min/1.73m2, respectively, P <.007). Cystatin value was significantly higher in metabolic syndrome patients than in others (0.86±0.23 vs 0.79±0.20 mg/L, respectively, P <.0001), independently of serum creatinine level and creatinine clearance. Furthermore, there was a progressive increase in cystatin, as a function of the number of metabolic syndrome components.

Conclusions

Our study shows that cystatin is associated with metabolic syndrome in dyslipidemic patients. Cystatin may be an interesting marker of metabolic syndrome and of increased cardiovascular and renal risk.

Keywords: Cardiovascular risk, Cystatin C, Glomerular function rate, High blood pressure, Hypertriglyceridemia, Metabolic syndrome, Waist circumference

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9343(08)00150-2

doi:10.1016/j.amjmed.2008.01.040

The American Journal of Medicine
Volume 121, Issue 5 , Pages 426-432, May 2008